Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Divi's Laboratories Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹6,755.00 |
|---|---|
| Day's Range | ₹6,693.00 - ₹6,864.50 |
| Open | ₹6,784.00 |
| 52 Week Range | ₹5,636.50 - ₹7,071.50 |
| Volume | 3,58,137 |
| Market Cap | ₹0.18 |
| Previous Close | ₹6,744.35 |
|---|---|
| Day's Range | ₹6,696.15 - ₹6,862.00 |
| Open | ₹6,799.95 |
| 52 Week Range | ₹5,637.50 - ₹7,077.70 |
| Volume | 43,971 |
| Market Cap | ₹0.18 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 24,192.15 |
|---|---|
| Market Cap (₹ in Mn) | 0.18 |
| Dividend Yield(%) | 0.44 |
| Price/Earning (TTM) | 69.99 |
| TTM EPS (₹) | 96.73 |
| P/E Ratio | 69.83 |
| Book Value(₹) | 10.72 |
| PAT Margin (%) | 23.29 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 20.45 |
| Trade Value ( ₹ in Lacs) | 2,965.56 |
|---|---|
| Market Cap (₹ in Mn) | 0.18 |
| Dividend Yield(%) | 0.44 |
| Price/Earning (TTM) | 69.99 |
| TTM EPS (₹) | 96.73 |
| P/E Ratio | 69.83 |
| Book Value(₹) | 10.72 |
| PAT Margin (%) | 23.29 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 20.45 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 25360.0 | 91980.0 |
| Expenses | N/A | N/A |
| PBT | 8610.0 | 29290.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 6670.0 | 22090.0 |
About Divi's Laboratories Ltd.
| Founded | 1990 |
|---|---|
| Managing Director | Murali K Divi |
| NSE Symbol | DIVISLAB |
Latest News
Divis Laboratories informs about deduction of Income tax at source from payment of dividend
Hester Biosciences informs about corrigendum to AGM notice
Pursuant to applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hester Biosciences has informed that it enclosed Corrigendum to the Notice for the Annual General Meeting scheduled to be held on Tuesday, 21 July 2026 at 10:30 am (IST) through Video Conference / Other Audio-Visual Means. Post-dispatch of the notice, it has come to the attention of the Company that due to an inadvertent typographical/ clerical error, one of the remuneration terms appearing in the Explanatory Statement to the resolution set out at Item No. 6 of the AGM Notice, relating to the re-appointment of the Executive Director of the Company, was incorrectly mentioned on page no. 17 of the AGM Notice. Accordingly, the company has informed that the gross salary shall be read as INR 10 lakh per month instead of INR 8.40 lakh per month, as mentioned in the Explanatory Statement. The said correction is only to rectify the inadvertent typographical / clerical error and is in line with the remuneration terms approved by the Board of Directors while considering the re-appointment of the Executive Director. This Corrigendum shall form an integral part of and should be read in conjunction with the Notice of the 39th Annual General Meeting. In view of the aforesaid, the inadvertent mistake is now rectified and the notice with the updated explanatory statement is attached.
The above information is a part of company’s filings submitted to BSE.
JB Chemicals & Pharmaceuticals informs about amalgamation updates
Amrutanjan Health Care informs about certificate
Marksans Pharma informs about acquisition
Marksans Pharma has informed that the company entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany based pharmaceutical company with frontend sales, marketing, and distribution capabilities across German healthcare market. The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union. The company has enclosed the details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/ 4/2015 dated September 9, 2015 given in Annexure A to this letter.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Divi's Laboratories Ltd. is ₹6,755.00 as of 2026-07-08.
The market capitalisation of Divi's Laboratories Ltd. is ₹179,736.83 as of 2026-07-07.
The 1-year return of Divi's Laboratories Ltd. is -133.50% as of 2026-07-08.
The P/E ratio of Divi's Laboratories Ltd. is 69.83 as of 2026-07-08.
The 52-week high and low of Divi's Laboratories Ltd. are ₹7,071.50 and ₹5,636.50, respectively, as of 2026-07-08.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
